R Mehta

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi request reprint Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study
    Rashmi Mehta
    GlaxoSmithKline, Research Triangle Park, North Carolina Electronic address
    Clin Ther 36:1016-1027.e2. 2014
  2. pmc Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study
    Rashmi Mehta
    Respiratory Medicines Development Center, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Int J Chron Obstruct Pulmon Dis 8:159-67. 2013
  3. pmc Bioavailability of inhaled fluticasone propionate via chambers/masks in young children
    K Blake
    Center for Pharmacogenomics and Translational Research, Dept of Biomedical Research, Nemours Children s Clinic, Jacksonville, FL, USA
    Eur Respir J 39:97-103. 2012

Collaborators

  • K Blake
  • T Spencer
  • L Hendeles
  • R L Kunka

Detail Information

Publications3

  1. ncbi request reprint Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study
    Rashmi Mehta
    GlaxoSmithKline, Research Triangle Park, North Carolina Electronic address
    Clin Ther 36:1016-1027.e2. 2014
    ..Preclinical and clinical data suggest that UMEC and VI are predominantly eliminated by the liver...
  2. pmc Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study
    Rashmi Mehta
    Respiratory Medicines Development Center, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Int J Chron Obstruct Pulmon Dis 8:159-67. 2013
    ....
  3. pmc Bioavailability of inhaled fluticasone propionate via chambers/masks in young children
    K Blake
    Center for Pharmacogenomics and Translational Research, Dept of Biomedical Research, Nemours Children s Clinic, Jacksonville, FL, USA
    Eur Respir J 39:97-103. 2012
    ..VHCs are not interchangeable, as differences in drug delivery to the lung may occur. A population pharmacokinetic approach can be used to determine lung bioavailability of FP...